.svg){kind=icon}
Medical cannabis conversations can quickly move from science into personal experience. One patient may say a particular product transformed their sleep, while another may feel very little from the same cannabinoid amount. A laboratory study may suggest that a terpene has interesting biological activity, while human clinical evidence remains limited.
Evidence-based cannabis medicine provides a framework for making sense of those differences.
The goal is not to dismiss patient experience or wait for perfect research before making every decision. It is to combine the best available scientific evidence with clinical judgment, patient goals, product quality, safety considerations, and careful monitoring.
For Florida medical cannabis patients, that means looking beyond THC percentages, strain names, and marketing claims and asking a more useful question: What does the evidence actually support for this patient, this symptom, this product, and this dose?
Principle 1: Start With a Specific Treatment Goal
“Using cannabis for wellness” is difficult to evaluate.
A more useful goal is specific and measurable. Examples might include reducing nighttime awakenings, improving appetite, decreasing nausea episodes, reducing pain enough to complete daily activities, or limiting reliance on another symptom-management strategy under medical supervision.
Specific goals make it easier to determine whether cannabis is actually helping.
Patients can track:
- The symptom being targeted
- Baseline severity
- Product and batch
- Amount used
- Administration route
- Time of use
- Onset
- Duration
- Functional improvement
- Unwanted effects
A cannabis product that creates noticeable intoxication without improving the intended symptom should not automatically be considered effective.
Principle 2: Match the Claim to the Evidence
Cannabis evidence varies considerably by medical condition.
Some cannabinoids have been studied extensively for specific indications, while evidence for other uses comes mainly from small trials, observational studies, animal research, or laboratory experiments.
These levels of evidence should not be treated as equal.
A finding in isolated cells can help researchers understand a possible mechanism, but it does not prove that a dispensary product treats a disease in humans.
Similarly, a survey showing that patients report feeling better can be valuable but cannot establish cause and effect as strongly as a well-designed randomized clinical trial.
Evidence-based cannabis education should clearly distinguish among:
- Established clinical uses
- Promising but incomplete evidence
- Early experimental findings
- Patient-reported experience
- Unsupported marketing claims
“More research is needed” is sometimes the most scientifically accurate conclusion.
Principle 3: Know Exactly What Product Is Being Used
Cannabis is not one medication.
A whole-flower product containing THC, CBD, minor cannabinoids, and cannabis terpenes is chemically different from a purified cannabinoid. A vaporizer concentrate behaves differently from an edible. A fast-acting chew may use a different formulation than a traditional gummy.
Product information should include more than an indica, sativa, or hybrid label.
Patients should review:
- THC concentration
- CBD concentration
- Minor cannabinoids when available
- Terpene profile
- Serving size
- Administration route
- Product formulation
- Batch-specific laboratory information
- Ingredients
- Storage instructions
This is especially important when trying to reproduce a successful experience. A familiar strain name does not guarantee that a future batch will have exactly the same cannabinoid and terpene composition.
Principle 4: Dose Matters
Cannabis effects can change significantly as the dose increases.
A small amount of THC may feel manageable while a larger amount can cause dizziness, anxiety, sedation, impaired coordination, rapid heart rate, or an uncomfortable level of intoxication.
More THC is therefore not automatically better medicine.
The practical goal is generally to identify a controlled amount that supports the intended symptom goal without creating unnecessary side effects.
Patients should follow the dosing plan established with their medical cannabis physician and make changes gradually rather than increasing multiple variables at once.
When evaluating a new product, it helps to keep the product, administration method, and timing consistent before deciding whether the dose should change.
Principle 5: Administration Route Changes the Evidence
Ten milligrams printed on one product cannot automatically be compared with ten milligrams delivered through another route.
Inhaled cannabis generally produces a relatively fast onset because cannabinoids enter circulation through the lungs.
Swallowed THC has a slower onset and passes through the digestive system and liver, where some is converted into 11-hydroxy-THC. This can create a longer-lasting and sometimes more intense experience.
Sublingual products, topicals, and transdermal products introduce additional differences in absorption.
The administration route affects:
- Onset
- Duration
- Bioavailability
- Metabolism
- Dose control
- Potential side effects
Evidence from a clinical trial using an oral cannabinoid should not automatically be applied to smoked flower or a concentrated vaporizer.
Principle 6: Monitor Benefits and Harms Together
Evidence-based medicine does not evaluate effectiveness separately from safety.
A treatment that improves one symptom while creating substantial impairment, anxiety, cardiovascular effects, vomiting, or medication interactions may not represent a favorable tradeoff.
Patients should monitor both sides of the equation.
Potential cannabis-related effects can include dizziness, sedation, anxiety, impaired memory, altered coordination, increased heart rate, nausea, and changes in judgment.
Frequent cannabis use may also create tolerance, dependence, or cannabis use disorder in some individuals.
Patients should tell healthcare providers about cannabis use, particularly when taking prescription medications.
Principle 7: Be Careful With Terpene Claims
Cannabis terpenes are scientifically interesting compounds.
Myrcene, limonene, pinene, linalool, humulene, beta-caryophyllene, and other terpenes are being investigated for a range of potential biological effects.
However, many popular terpene claims extend beyond the available human evidence.
A laboratory finding involving isolated beta-caryophyllene, for example, does not prove that a cannabis strain containing that terpene will produce a particular medical result.
Terpene profiles can still be useful for product identification and comparison. Patients may discover that they consistently prefer certain chemical profiles.
That personal pattern is useful information—but it should not be presented as universal medical proof.
Principle 8: Consider Medication Interactions and Medical History
THC and CBD can interact with medications and may affect patients differently based on underlying medical conditions.
Extra caution may be appropriate for people taking sedatives, blood thinners, seizure medications, cardiovascular drugs, immune-modifying medications, or other medicines requiring careful monitoring.
Cannabis may also require additional consideration in patients with cardiovascular conditions, a history of severe psychiatric reactions, respiratory disease when using inhaled products, or a history of problematic substance use.
Evidence-based cannabis medicine should consider the complete patient rather than focusing only on the cannabis product.
Principle 9: Patient Experience Still Matters
Clinical evidence describes what happens across groups of people. Individual treatment decisions involve one patient.
A clinical trial might find a modest average benefit while some participants experience substantial improvement and others experience no benefit.
That variation does not make research irrelevant. It explains why careful individual monitoring matters.
Patient experience should complement scientific evidence—not replace it.
Keeping a simple cannabis journal can help identify patterns involving product, dose, time, meals, symptom response, duration, and side effects.
Green Dragon Florida Products as Evidence-Based Examples
The following products illustrate why format, potency, and dose should be considered separately. They are not presented as treatments for any particular medical condition.
PLUS Blackberry Lemonade Chews — Live Oak
PLUS Blackberry Lemonade Chews contain 100 mg of total THC per package, with the current listing describing 5 mg of THC per chew.
A pre-portioned edible provides a clearer unit dose than inhaled flower, but oral absorption can still vary according to meals, digestion, metabolism, and individual tolerance.
Everyday Stardust All-in-One — Stuart
Everyday Stardust All-in-One is a one-gram vaporizer currently listed at 72.5% THC with 6.338% total terpenes.
The laboratory profile provides useful information, but the actual dose received from each inhalation still depends on draw length, frequency, device performance, and patient technique.
Circles Dreamy Crumble Flower — Orlando
Circles Dreamy Crumble Flower is a 3.5-gram flower product currently listed at 23.6% THC and approximately 1.89% total terpenes.
Flower illustrates why batch-specific laboratory information matters. Even when a patient purchases the same cultivar again, the cannabinoid and terpene profile may change.
Product availability and laboratory results can vary by Green Dragon Florida location.
The Green Dragon Takeaway
Evidence-based cannabis medicine means balancing research with real-world patient care.
Begin with a defined goal. Choose a clearly characterized product. Understand the dose and administration route. Monitor benefits and adverse effects. Consider medication interactions. Be skeptical of claims that go beyond the evidence.
Most importantly, do not mistake higher potency, a popular strain, or an interesting laboratory finding for proof of medical effectiveness.
The best cannabis decision is an informed one—supported by evidence, individualized to the patient, and evaluated over time.